scholarly journals Evaluation of the Role of BRAFV600E Somatic Mutation on Papillary Thyroid Cancer Disease Persistence: A Prospective Study

2018 ◽  
Vol 7 (5) ◽  
pp. 251-257 ◽  
Author(s):  
Luca Damiani ◽  
Sabrina Lupo ◽  
Roberta Rossi ◽  
Stefania Bruni ◽  
Mirco Bartolomei ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prospective Study ◽  
Papillary Thyroid Cancer ◽  
Somatic Mutation ◽  
Papillary Thyroid ◽  
Cancer Disease ◽  
A Prospective Study ◽  
Disease Persistence

The Role of Different Molecular Markers in Papillary Thyroid Cancer Patients with Acromegaly

2018 ◽  
Vol 127 (07) ◽  
pp. 437-444 ◽  
Author(s):  
Fatma Ela Keskin ◽  
Hande Mefkure Ozkaya ◽  
Sina Ferahman ◽  
Ozlem Haliloglu ◽  
Adem Karatas ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Ex Vivo ◽  
Papillary Thyroid ◽  
Cerrahpasa Medical Faculty ◽  
Protein Expressions ◽  
Galectin 3 ◽  
Benign Nodules ◽  
Igf1 Expression

Abstract Purpose Prevalence of papillary thyroid cancer (PTC) is increased in patients with acromegaly. We aimed to determine the protein expression of BRAF, RAS, RET, insulin like growth factor 1(IGF1), Galectine 3, CD56 in patients with PTC related acromegaly and to compare the extensity of these expressions with normal PTC patients and benign thyroid nodules. Methods We studied 313 patients with acromegaly followed in Cerrahpasa Medical Faculty, Endocrinology and Metabolism Clinic between 1998 and 2015. On the basis of availability of pathological specimen of thyroid tissues, thyroid samples of 13 patients from 19 with acromegaly related PTC (APTC), 20 normal PTC and 20 patients with multinodulary goiter (MNG) were histopathologically evaluated. Protein expressions were determined via immunohistochemical staining in ex-vivo tumor samples and benign nodules. Results The incidence of PTC in acromegaly patients were 6% (n=19). Among patients with PTC, APTC and MNG, all the immunohistochemical protein expressions we have studied were higher in papillary thyroid cancer groups (p<0.01, for all). Between PTC group without acromegaly and APTC, galectin 3 and IGF1 expression was significantly higher in acromegalic patients (p<0.01 for all) while RAS was predominantly higher in PTC patients without acromegaly (p<0.01). Conclusion BRAF expression was not higher in PTC with acromegaly patients compared to PTC patients without acromegaly. Galectine 3 and IGF1 were expressed more intensively in APTC. These positive protein expressions may have more influence on determining malign nodules among acromegaly patients.

scholarly journals The Role of miRNA in Papillary Thyroid Cancer in the Context of miRNA Let-7 Family

2016 ◽  
Vol 17 (6) ◽  
pp. 909 ◽  
Author(s):  
Ewelina Perdas ◽  
Robert Stawski ◽  
Dariusz Nowak ◽  
Maria Zubrzycka
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid

scholarly journals The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer

2020 ◽  
Vol 39 (1) ◽  
Author(s):  
Carla Colombo ◽  
Emanuela Minna ◽  
Chiara Gargiuli ◽  
Marina Muzza ◽  
Matteo Dugo ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Mirna Expression ◽  
Expression Profiles ◽  
Expression Patterns ◽  
Tissue Type ◽  
Molecular Profile ◽  
Papillary Thyroid ◽  
Primary Tumors ◽  
Disease Persistence

Abstract Background Papillary thyroid cancer (PTC) is the most frequent endocrine tumor. Radioiodine (RAI) treatment is highly effective in these tumors, but up to 60% of metastatic cases become RAI-refractory. Scanty data are available on either the molecular pattern of radioiodine refractory papillary thyroid cancers (PTC) or the mechanisms responsible for RAI resistance. Methods We analyzed the molecular profile and gene/miRNA expression in primary PTCs, synchronous and RAI-refractory lymph node metastases (LNMs) in correlation to RAI avidity or refractoriness. We classified patients as RAI+/D+ (RAI uptake/disease persistence), RAI−/D+ (absent RAI uptake/disease persistence), and RAI+/D- (RAI uptake/disease remission), and analyzed the molecular and gene/miRNA profiles, and the expression of thyroid differentiation (TD) related genes. Results A different molecular profile according to the RAI class was observed: BRAFV600E cases were more frequent in RAI−/D+ (P = 0.032), and fusion genes in RAI+/D+ cases. RAI+/D- patients were less frequently pTERT mutations positive, and more frequently wild type for the tested mutations/fusions. Expression profiles clearly distinguished PTC from normal thyroid. On the other hand, in refractory cases (RAI+/D+ and RAI−/D+) no distinctive PTC expression patterns were associated with either tissue type, or RAI uptake, but with the driving lesion and BRAF−/RAS-like subtype. Primary tumors and RAI-refractory LNMs with BRAFV600E mutation display transcriptome similarity suggesting that RAI minimally affects the expression profiles of RAI-refractory metastases. Molecular profiles associated with the expression of TPO, SLC26A4 and TD genes, that were found more downregulated in BRAFV600E than in gene fusions tumors. Conclusions The present data indicate a different molecular profile in RAI-avid and RAI-refractory metastatic PTCs. Moreover, BRAFV600E tumors displayed reduced differentiation and intrinsic RAI refractoriness, while PTCs with fusion oncogenes are RAI-avid but persistent, suggesting different oncogene-driven mechanisms leading to RAI refractoriness.

Role of Prophylactic Thyroid Neck Dissection in Papillary Thyroid Cancer

2017 ◽  
Vol 69 (6) ◽  
pp. 2694-2697
Author(s):  
Hisham Sameer Alhathloul ◽  
Mohammed Ahmed Almasabi ◽  
Abdulghani Mohammad Lodhi
Keyword(s):  
Thyroid Cancer ◽  
Neck Dissection ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid

Role of P53, E-cadherin and BRAF as predictors of regional nodal recurrence for papillary thyroid cancer

2019 ◽  
Vol 40 ◽  
pp. 59-65 ◽  
Author(s):  
Khadiga M. Ali ◽  
Shadi Awny ◽  
Dina Abdallah Ibrahim ◽  
Islam H. Metwally ◽  
Omar Hamdy ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Nodal Recurrence ◽  
Regional Nodal Recurrence ◽  
E Cadherin

scholarly journals Papillary Thyroid Cancer-Promoting Activities of Combined Oral Contraceptive Components

2020 ◽  
Vol 9 ◽  
pp. 1648
Author(s):  
Mehdi Hedayati ◽  
Sadegh Rajabi ◽  
Abdolrahim Nikzamir
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Reproductive Age ◽  
Papillary Thyroid ◽  
Scratch Assay ◽  
Diphenyltetrazolium Bromide ◽  
High Incidence ◽  
And Migration ◽  
The Relationship

Background: Thyroid cancer is more common in women at reproductive age, suggesting the relationship between its high-incidence and therapeutic use of hormonal medications, such as oral contraceptives (OCPs). The aim of this study was to identify the effect of low-dose combined OCP (LD-COC) on proliferation, apoptosis, and migration of human papillary thyroid cancer (PTC) BCPAP cell line. Materials and Methods: BCPAP cells were cultured and treated with the combination of 90nM levonorgestrel (LNG) and 20nM ethinylestradiol (EE) for 48 hours. Afterward, using 3-(4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide (MTT) assay, the proliferation of the cells was measured. Apoptosis was determined by using a Caspase-3 ELISA kit. Migratory properties of combined LNG and EE were studied through wound scratch assay. The expression levels of pro-apoptotic factor BAX, anti-apoptotic factor Bcl2, and proliferation marker Ki67 were analyzed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and western blotting. Results: Upon treatment with the combination of LNG and EE, proliferation and migration of BCPAP cells were significantly enhanced. However, LNG and EE remarkably inhibited apoptosis of these cells. Furthermore, treating PTC cells with combined LNG and EE caused a marked increase in the expression of Bcl2 and Ki67 and a considerable decrease in BAX levels (P˂ 0.05). Conclusion: Our data linked the use of COCs and the progression and aggressiveness of PTC, suggesting the role of these hormonal compounds as promoting factors for PTC tumors. Despite these observations, further investigations will be required to fully establish the pathogenic impact of these medications on PTC. [GMJ.2020;9:e1648] 

scholarly journals Risk factors of permanent hypoparathyroidism after total thyroidectomy and central neck dissection for papillary thyroid cancer: a prospective study

2020 ◽  
Vol 71 (2) ◽  
pp. 126-133
Author(s):  
Paulina Godlewska ◽  
Małgorzata Benke ◽  
Elżbieta Stachlewska-Nasfeter ◽  
Jacek Gałczyński ◽  
Bartosz Puła ◽  
...  
Keyword(s):  
Risk Factors ◽  
Thyroid Cancer ◽  
Prospective Study ◽  
Total Thyroidectomy ◽  
Neck Dissection ◽  
Central Neck Dissection ◽  
Central Neck ◽  
Permanent Hypoparathyroidism ◽  
Papillary Thyroid ◽  
A Prospective Study
Sign in / Sign up

Export Citation Format

Share Document